International Clinical Trials Day 2026, a year in review: Access to Trials
CLINICAL TRIALS IN REGIONAL, RURAL AND REMOTE AUSTRALIA
With
Amanda Koegelenberg,
CEO, Novatrials
INTERNATIONAL CLINICAL TRIALS DAY SERIES SEGMENT
Filmed in Newcastle, NSW | May 2026
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leading up to 20th May with interviews captured across Australia. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials. The first segment is an example of how in-person clinical trial access has improved for regional, rural and remote communities.
Novatrials is helping transform access to clinical trials for people living in regional, rural and remote communities across the Hunter New England region and beyond. Based in Newcastle, New South Wales, the organisation was founded with a vision to bring innovative medical treatments closer to communities that have traditionally faced significant travel barriers to access state-of-the-art healthcare.
With the first purpose-built Phase 1 clinical trial facility outside of an Australian capital city, Novatrials is expanding opportunities for participants across Newcastle, the wider Hunter region and regional New South Wales to take part in world-class research closer to home. By conducting Phase 1 through to Phase 4 studies across a range of therapeutic areas, the organisation is helping bridge the gap between laboratory innovation and real-world patient care.
According to CEO Amanda Koegelenberg, the investment in the facility illustrates Novatrials’ commitment to ensuring people in regional and remote areas no longer need to travel vast distances to participate in clinical trials, while also bringing more research investment, innovation and healthcare opportunities into the Hunter New England region.
The segment highlights how Novatrials is working collaboratively with partners including the University of Newcastle, Hunter Medical Research Institute and Hunter New England Local Health District to strengthen the region’s research ecosystem and improve access to emerging treatments for local communities.
Source: Adapted from transcript using AI
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
-
Research, Mentorship and the PhD Experience
Pancreatic cancer remains one of the deadliest cancers, with survival rates below 10 per cent and treatments often as harsh as the disease itself.
Finding better ways to treat one of the deadliest cancers has become the focus of a University of Wollongong research team, where the relationship between a PhD supervisor and candidate has also played an important role in shaping the next generation of researchers.
-
In development, age specific clinical practice guidelines for early onset bowel cancer
The National Health and Medical Research Council (NHMRC) has agreed to consider for approval the Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer (EOCRC), to be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC), and funded by Bowel Cancer Australia. ALEC is led by Cochrane Australia and based in the School of Public Health and Preventive Medicine at Monash University.
